Cinnamon ameliorates experimental allergic encephalomyelitis in mice via regulatory T cells: Implications for multiple sclerosis therapy

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Mondal, Susanta ^a   Pahan, Kalipada ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN; TRANSCRIPTION FACTOR FOXP3; LYMPHOCYTE ANTIGEN RECEPTOR; PLANT EXTRACT; PLP1 PROTEIN, MOUSE; PROTEOLIPID PROTEIN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CINNAMOMUM; CINNAMONUM VERUM; DEMYELINATION; DIETARY INTAKE; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNOMODULATION; MALE; MONONUCLEAR CELL; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; POWDER; REGULATORY T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION; ANIMAL; C57BL MOUSE; CHEMISTRY; CINNAMOMUM ZEYLANICUM; CYTOLOGY; DEMYELINATING DISEASE; DISEASE MODEL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENETICS; IMMUNOLOGY; INCIDENCE; METABOLISM; MYELIN SHEATH; ORAL DRUG ADMINISTRATION; PATHOLOGY; SPINAL CORD; TH17 CELL; TRANSGENIC MOUSE;

ANIMALIA; CINNAMOMUM VERUM; MUS; MUS MUSCULUS;

ADMINISTRATION, ORAL; ANIMALS; BLOOD-BRAIN BARRIER; CINNAMOMUM ZEYLANICUM; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INCIDENCE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; MYELIN PROTEOLIPID PROTEIN; MYELIN SHEATH; PLANT EXTRACTS; RECEPTORS, ANTIGEN, T-CELL; SPINAL CORD; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84920774516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116566     Document Type: Article

References (44)

1. Coffer PJ, Burgering BM (2004) Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 4: 889-899. doi: 10.1038/nri1488 PMID: 15516968
2. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061. doi: 10.1126/science.1079490 PMID: 12522256
3. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352. doi: 10.1038/ni1178 PMID: 15785760
4. Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, et al. (2005) Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 81: 45-52. doi: 10.1002/jnr.20522 PMID: 15952173
5. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199: 971-979. doi: 10.1084/jem.20031579 PMID: 15067033
6. Paust S, Cantor H (2005) Regulatory T cells and autoimmune disease. Immunol Rev 204: 195-207. doi: 10.1111/j.0105-2896.2005.00247.x PMID: 15790360
7. McGeachy MJ, Stephens LA, Anderton SM (2005) Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 175: 3025-3032. doi: 10.4049/jimmunol.175.5.3025 PMID: 16116190
8. Venken K, Hellings N, Thewissen M, Somers V, Hensen K, et al. (2008) Compromised CD4+ CD25 (high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123: 79-89. doi: 10.1111/j.1365-2567.2007.02690.x PMID: 17897326
9. Pahan K (2010) Neuroimmune pharmacological control of EAE. J Neuroimmune Pharmacol 5: 165-167. doi: 10.1007/s11481-010-9219-6 PMID: 20414732
10. Pahan K (2011) Immunomodulation of experimental allergic encephalomyelitis by cinnamon metabolite sodium benzoate. Immunopharmacol Immunotoxicol 33: 586-593. doi: 10.3109/08923973.2011.561861 PMID: 21425926
11. Dasgupta S, Jana M, Zhou Y, Fung YK, Ghosh S, et al. (2004) Antineuroinflammatory effect of NF-kappaB essential modifier-binding domain peptides in the adoptive transfer model of experimental allergic encephalomyelitis. J Immunol 173: 1344-1354. doi: 10.4049/jimmunol.173.2.1344 PMID: 15240729
12. Dasgupta S, Zhou Y, Jana M, Banik NL, Pahan K (2003) Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. J Immunol 170: 3874-3882. doi: 10.4049/jimmunol.170.7.3874 PMID: 12646656
13. Brahmachari S, Pahan K (2007) Sodium benzoate, a food additive and a metabolite of cinnamon, modifies T cells at multiple steps and inhibits adoptive transfer of experimental allergic encephalomyelitis. J Immunol 179: 275-283. doi: 10.4049/jimmunol.179.1.275 PMID: 17579047
14. Mondal S, Roy A, Pahan K (2009) Functional blocking monoclonal antibodies against IL-12p40 homodimer inhibit adoptive transfer of experimental allergic encephalomyelitis. J Immunol 182: 5013-5023. doi: 10.4049/jimmunol.0801734 PMID: 19342681
15. Jana A, Modi KK, Roy A, Anderson JA, van Breemen RB, et al. (2013) Up-regulation of neurotrophic factors by cinnamon and its metabolite sodium benzoate: therapeutic implications for neurodegenerative disorders. J Neuroimmune Pharmacol 8: 739-755. doi: 10.1007/s11481-013-9447-7 PMID: 23475543
16. Khasnavis S, Pahan K (2014) Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neuroimmune Pharmacol 9: 569-581. doi: 10.1007/s11481-014-9552-2 PMID: 24946862
17. Brahmachari S, Pahan K (2010) Myelin basic protein priming reduces the expression of Foxp3 in T cells via nitric oxide. J Immunol 184: 1799-1809. doi: 10.4049/jimmunol.0804394 PMID: 20083653
18. Brahmachari S, Pahan K (2009) Suppression of regulatory T cells by IL-12p40 homodimer via nitric oxide. J Immunol 183: 2045-2058. doi: 10.4049/jimmunol.0800276 PMID: 19587012
19. Pahan K, Sheikh FG, Namboodiri AM, Singh I (1997) Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100: 2671-2679. doi: 10.1172/JCI119812 PMID: 9389730
20. Waldner H, Whitters MJ, Sobel RA, Collins M, Kuchroo VK (2000) Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor. Proc Natl Acad Sci U S A 97: 3412-3417. doi: 10.1073/pnas.97.7.3412 PMID: 10737797
21. Kuerten S, Lehmann PV (2011) The immune pathogenesis of experimental autoimmune encephalomyelitis: lessons learned for multiple sclerosis? J Interferon Cytokine Res 31: 907-916. doi: 10.1089/jir.2011.0072 PMID: 21936633
22. Martin R, McFarland HF, McFarlin DE (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10: 153-187. doi: 10.1146/annurev.iy.10.040192.001101 PMID: 1375472
23. Chun J, Hartung (2010) HP Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33: 91-101. doi: 10.1097/WNF.0b013e3181cbf825 PMID: 20061941
24. El-behi M, Rostami A, Ciric B (2010) Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol 5: 189-197. doi: 10.1007/s11481-009-9188-9 PMID: 20107924
25. Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, et al. (2009) CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326: 986-991. doi: 10.1126/science.1172702 PMID: 19797626
26. Shi G, Cox CA, Vistica BP, Tan C, Wawrousek EF, et al. (2008) Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells. J Immunol 181: 7205-7213. doi: 10.4049/jimmunol.181.10.7205 PMID: 18981142
27. Schrempf W, Ziemssen T (2007) Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 6: 469-475. doi: 10.1016/j.autrev.2007.02.003 PMID: 17643935
28. Zhu J, Paul WE (2010) CD4+ T cell plasticity-Th2 cells join the crowd. Immunity 32: 11-13. doi: 10.1016/j.immuni.2010.01.001 PMID: 20152167
29. Dasgupta S, Roy A, Jana M, Hartley DM, Pahan K (2007) Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol Pharmacol 72: 934-946. doi: 10.1124/mol.106.033787 PMID: 17625103
30. Miller A (1997) Current and investigational therapies used to alter the course of disease in multiple sclerosis. South Med J 90: 367-375. doi: 10.1097/00007611-199704000-00001 PMID: 9114824
31. Cohen JA, Reingold SC, Polman CH, Wolinsky JS (2012) Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol 11: 467-476. doi: 10.1016/S1474-4422(12)70059-5 PMID: 22516081
32. Abd El-Mawla AM, Schmidt W, Beerhues L (2001) Cinnamic acid is a precursor of benzoic acids in cell cultures of Hypericum androsaemum L. but not in cell cultures of Centaurium erythraea RAFN. Planta 212: 288-293.
33. Bridges JW, French MR, Smith RL, Williams RT (1970) The fate of benzoic acid in various species. Biochem J 118: 47-51. PMID: 4990586
34. Kubota K, Ishizaki T (1991) Dose-dependent pharmacokinetics of benzoic acid following oral administration of sodium benzoate to humans. Eur J Clin Pharmacol 41: 363-368. doi: 10.1007/BF00314969 PMID: 1804654
35. Leonard JV, Morris AA (2002) Urea cycle disorders. Semin Neonatol 7: 27-35. doi: 10.1053/siny.2001.0085 PMID: 12069536
36. Scaglia F, Carter S, O'Brien WE, Lee B (2004) Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol Genet Metab 81 Suppl 1: S79-85. doi: 10.1016/j.ymgme.2003.11.017 PMID: 15050979
37. Nair B (2001) Final report on the safety assessment of Benzyl Alcohol, Benzoic Acid, and Sodium Benzoate. Int J Toxicol 20 Suppl 3: 23-50. PMID: 11766131
38. Ziegler SF (2006) FOXP3: of mice and men. Annu Rev Immunol 24: 209-226. doi: 10.1146/annurev.immunol.24.021605.090547 PMID: 16551248
39. Brahmachari S, Jana A, Pahan K (2009) Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J Immunol 183: 5917-5927. doi: 10.4049/jimmunol.0803336 PMID: 19812204
40. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, et al. (2007) IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37: 3021-3029. doi: 10.1002/eji.200737810 PMID: 17874423
41. Xu D, Liu H, Komai-Koma M, Campbell C, McSharry C, et al. (2003) CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J Immunol 170: 394-399. doi: 10.4049/jimmunol.170.1.394 PMID: 12496424
42. Reddy J, Waldner H, Zhang X, Illes Z, Wucherpfennig KW, et al. (2005) Cutting edge: CD4+CD25+ regulatory T cells contribute to gender differences in susceptibility to experimental autoimmune encephalomyelitis. J Immunol 175: 5591-5595. doi: 10.4049/jimmunol.175.9.5591 PMID: 16237044
43. McKee AS, Pearce EJ (2004) CD25+CD4+ cells contribute to Th2 polarization during helminth infection by suppressing Th1 response development. J Immunol 173: 1224-1231. doi: 10.4049/jimmunol.173.2.1224 PMID: 15240714
44. Kohm AP, Carpentier PA, Anger HA, Miller SD (2002) Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 169: 4712-4716. doi: 10.4049/jimmunol.169.9.4712 PMID: 12391178